-
Something wrong with this record ?
Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines
E. Koziolová, P. Chytil, T. Etrych, O. Janoušková,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acrylamides administration & dosage pharmacology MeSH
- Drug Resistance, Neoplasm MeSH
- Doxorubicin administration & dosage pharmacology MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Neuroblastoma drug therapy metabolism MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 antagonists & inhibitors biosynthesis MeSH
- Antineoplastic Combined Chemotherapy Protocols pharmacology MeSH
- Ritonavir administration & dosage pharmacology MeSH
- Drug Screening Assays, Antitumor MeSH
- Drug Synergism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Polymer prodrugs can considerably improve the treatment of tumors with multidrug resistance, often caused by overexpression of P-glycoprotein (P-gp). Here, we present the effect of the N-(2-hydroxypropyl) methacrylamide-based polymer conjugate with P-gp inhibitor ritonavir (RIT) on the increase of free doxorubicin (DOX) and polymer-bound DOX cytotoxicity in the human neuroblastoma 4 cell line and its resistant clones to different cytostatics. The increase in cytotoxicity after polymer-RIT conjugate pretreatment was higher for the lines overexpressing P-gp and less pronounced for those with decreased P-gp levels. Moreover, the effect of polymer conjugate containing inhibitor and DOX on the same polymer chain was lower than that of two individual polymer conjugates used sequentially. In conclusion, the polymer-RIT conjugate can significantly increase the cytotoxicity of free DOX and polymer-DOX conjugates in cells with various multidrug resistance origins and can thus be considered a suitable therapeutic enhancer of polymer prodrugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010339
- 003
- CZ-PrNML
- 005
- 20180418101226.0
- 007
- ta
- 008
- 180404s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/CAD.0000000000000553 $2 doi
- 035 __
- $a (PubMed)28901962
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Koziolová, Eva $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague 6, Czech Republic.
- 245 10
- $a Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines / $c E. Koziolová, P. Chytil, T. Etrych, O. Janoušková,
- 520 9_
- $a Polymer prodrugs can considerably improve the treatment of tumors with multidrug resistance, often caused by overexpression of P-glycoprotein (P-gp). Here, we present the effect of the N-(2-hydroxypropyl) methacrylamide-based polymer conjugate with P-gp inhibitor ritonavir (RIT) on the increase of free doxorubicin (DOX) and polymer-bound DOX cytotoxicity in the human neuroblastoma 4 cell line and its resistant clones to different cytostatics. The increase in cytotoxicity after polymer-RIT conjugate pretreatment was higher for the lines overexpressing P-gp and less pronounced for those with decreased P-gp levels. Moreover, the effect of polymer conjugate containing inhibitor and DOX on the same polymer chain was lower than that of two individual polymer conjugates used sequentially. In conclusion, the polymer-RIT conjugate can significantly increase the cytotoxicity of free DOX and polymer-DOX conjugates in cells with various multidrug resistance origins and can thus be considered a suitable therapeutic enhancer of polymer prodrugs.
- 650 _2
- $a P-glykoprotein $x antagonisté a inhibitory $x biosyntéza $7 D020168
- 650 _2
- $a akrylamidy $x aplikace a dávkování $x farmakologie $7 D000178
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x farmakologie $7 D000971
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a doxorubicin $x aplikace a dávkování $x farmakologie $7 D004317
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a neuroblastom $x farmakoterapie $x metabolismus $7 D009447
- 650 _2
- $a ritonavir $x aplikace a dávkování $x farmakologie $7 D019438
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chytil, Petr
- 700 1_
- $a Etrych, Tomáš
- 700 1_
- $a Janoušková, Olga
- 773 0_
- $w MED00179775 $t Anticancer Drugs $x 1473-5741 $g Roč. 28, č. 10 (2017), s. 1126-1130
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28901962 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180418101326 $b ABA008
- 999 __
- $a ok $b bmc $g 1287824 $s 1007151
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 28 $c 10 $d 1126-1130 $i 1473-5741 $m Anticancer Drugs $n Anticancer Drugs $x MED00179775
- LZP __
- $a Pubmed-20180404
